首页> 外文期刊>Therapeutic Drug Monitoring >Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
【24h】

Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.

机译:CYP2D6,CYP3A5和ABCB1的遗传多态性对日本精神分裂症患者的阿立哌唑及其活性代谢物dehydroaripiprazole稳态血药浓度的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The findings of this study suggest that CYP2D6 genotypes play an important role in controlling steady-state plasma concentrations of aripiprazole and the sum of aripiprazole and dehydroaripiprazole in Asian subjects, whereas CYP3A5 and ABCB1 genotypes seemed unlikely to have an impact.
机译:这项研究的发现表明,在亚洲受试者中,CYP2D6基因型在控制阿立哌唑的稳态血浆浓度以及阿立哌唑和脱氢阿立哌唑的总和中起着重要作用,而CYP3A5和ABCB1基因型似乎不太可能产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号